JP6933834B1 - 新型コロナウイルス感染者の重症化リスクの検査方法、その検査キット、コンパニオン診断薬及びその重症化リスクマーカー - Google Patents

新型コロナウイルス感染者の重症化リスクの検査方法、その検査キット、コンパニオン診断薬及びその重症化リスクマーカー Download PDF

Info

Publication number
JP6933834B1
JP6933834B1 JP2021523527A JP2021523527A JP6933834B1 JP 6933834 B1 JP6933834 B1 JP 6933834B1 JP 2021523527 A JP2021523527 A JP 2021523527A JP 2021523527 A JP2021523527 A JP 2021523527A JP 6933834 B1 JP6933834 B1 JP 6933834B1
Authority
JP
Japan
Prior art keywords
admission
fabp
urinary
concentration
aggravation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021523527A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2021255900A1 (https=
Inventor
大輔 片桐
大輔 片桐
英世 野入
英世 野入
貴夫 大曲
貴夫 大曲
健 菅谷
健 菅谷
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
TIMEWELL MEDICAL CO., LTD.
National Center for Global Health and Medicine
Original Assignee
TIMEWELL MEDICAL CO., LTD.
National Center for Global Health and Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by TIMEWELL MEDICAL CO., LTD., National Center for Global Health and Medicine filed Critical TIMEWELL MEDICAL CO., LTD.
Priority to JP2021130913A priority Critical patent/JP2022000635A/ja
Application granted granted Critical
Publication of JP6933834B1 publication Critical patent/JP6933834B1/ja
Publication of JPWO2021255900A1 publication Critical patent/JPWO2021255900A1/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/165—Coronaviridae, e.g. avian infectious bronchitis virus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/26—Infectious diseases, e.g. generalised sepsis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
JP2021523527A 2020-06-18 2020-06-18 新型コロナウイルス感染者の重症化リスクの検査方法、その検査キット、コンパニオン診断薬及びその重症化リスクマーカー Active JP6933834B1 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021130913A JP2022000635A (ja) 2020-06-18 2021-08-10 新型コロナウイルス感染者の重症化リスクの検査方法、その検査キット、コンパニオン診断薬及びその重症化リスクマーカー

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/JP2020/023982 WO2021255900A1 (ja) 2020-06-18 2020-06-18 新型コロナウイルス感染者の重症化リスクの検査方法、その検査キット、コンパニオン診断薬及びその重症化リスクマーカー

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021130913A Division JP2022000635A (ja) 2020-06-18 2021-08-10 新型コロナウイルス感染者の重症化リスクの検査方法、その検査キット、コンパニオン診断薬及びその重症化リスクマーカー

Publications (2)

Publication Number Publication Date
JP6933834B1 true JP6933834B1 (ja) 2021-09-08
JPWO2021255900A1 JPWO2021255900A1 (https=) 2021-12-23

Family

ID=77549998

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021523527A Active JP6933834B1 (ja) 2020-06-18 2020-06-18 新型コロナウイルス感染者の重症化リスクの検査方法、その検査キット、コンパニオン診断薬及びその重症化リスクマーカー
JP2021130913A Pending JP2022000635A (ja) 2020-06-18 2021-08-10 新型コロナウイルス感染者の重症化リスクの検査方法、その検査キット、コンパニオン診断薬及びその重症化リスクマーカー

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2021130913A Pending JP2022000635A (ja) 2020-06-18 2021-08-10 新型コロナウイルス感染者の重症化リスクの検査方法、その検査キット、コンパニオン診断薬及びその重症化リスクマーカー

Country Status (3)

Country Link
US (1) US20230221337A1 (https=)
JP (2) JP6933834B1 (https=)
WO (1) WO2021255900A1 (https=)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022030629A1 (ja) * 2020-08-07 2022-02-10 和幸 吉崎 ウイルス感染症状、治療法適合性、および／または治療結果を予測するための方法
WO2023007809A1 (ja) * 2021-07-29 2023-02-02 国立大学法人東北大学 コロナウイルス感染症の重症化リスクの評価方法、およびコロナウイルス感染症の重症化リスク評価キット
WO2023063021A1 (ja) * 2021-10-11 2023-04-20 国立大学法人大阪大学 患者の分類方法、キットおよびバイオマーカーの使用
JP2023088819A (ja) * 2021-12-15 2023-06-27 三洋化成工業株式会社 検査方法及び検査試薬

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2024029523A1 (https=) * 2022-08-02 2024-02-08

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020056621A (ja) * 2018-09-28 2020-04-09 シミックホールディングス株式会社 肝型脂肪酸結合タンパク質を定量する方法、その定量用キット、腎疾患の検査方法、その検査キット及びコンパニオン診断薬

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10973470B2 (en) * 2015-07-19 2021-04-13 Sanmina Corporation System and method for screening and prediction of severity of infection
US10689716B1 (en) * 2020-03-19 2020-06-23 University Of Miami Materials and methods for detecting coronavirus

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020056621A (ja) * 2018-09-28 2020-04-09 シミックホールディングス株式会社 肝型脂肪酸結合タンパク質を定量する方法、その定量用キット、腎疾患の検査方法、その検査キット及びコンパニオン診断薬

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
AN, P. ET AL.: "Biochemical indicators of coronavirus disease 2019 exacerbation and the clinical implications", PHARMACOLOGICAL RESEARCH, vol. 159, no. 104946, JPN6020034567, 23 May 2020 (2020-05-23), pages 1 - 7, ISSN: 0004538853 *
OKUBO, Y. ET AL.: "Increased Urinary Liver-Type Fatty Acid-Binding Protein Level Predicts Worsening Renal Function in P", JOURNAL OF CARDIAC FAILURE, vol. 24, no. 8, JPN6020034570, August 2018 (2018-08-01), pages 520 - 524, ISSN: 0004538855 *
WANG, C-Z. ET AL.: "Early risk factors of the exacerbation of coronavirus disease 2019 pneumonia", JOURNAL OF MEDICAL VIROLOGY, vol. Vol.2020;1-7, JPN6020034568, 29 May 2020 (2020-05-29), pages 1 - 7, ISSN: 0004538854 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022030629A1 (ja) * 2020-08-07 2022-02-10 和幸 吉崎 ウイルス感染症状、治療法適合性、および／または治療結果を予測するための方法
WO2023007809A1 (ja) * 2021-07-29 2023-02-02 国立大学法人東北大学 コロナウイルス感染症の重症化リスクの評価方法、およびコロナウイルス感染症の重症化リスク評価キット
WO2023063021A1 (ja) * 2021-10-11 2023-04-20 国立大学法人大阪大学 患者の分類方法、キットおよびバイオマーカーの使用
JP2023088819A (ja) * 2021-12-15 2023-06-27 三洋化成工業株式会社 検査方法及び検査試薬
JP7849689B2 (ja) 2021-12-15 2026-04-22 三洋化成工業株式会社 検査方法及び検査試薬

Also Published As

Publication number Publication date
WO2021255900A1 (ja) 2021-12-23
JP2022000635A (ja) 2022-01-04
US20230221337A1 (en) 2023-07-13
JPWO2021255900A1 (https=) 2021-12-23

Similar Documents

Publication Publication Date Title
JP6933834B1 (ja) 新型コロナウイルス感染者の重症化リスクの検査方法、その検査キット、コンパニオン診断薬及びその重症化リスクマーカー
JP5179011B2 (ja) 胎盤虚血および多臓器不全のモニタリング
JP5565607B2 (ja) 敗血症又は多臓器不全の予後診断方法及び予後診断用キット
AU2009318813A1 (en) Methods, devices and kits for detecting or monitoring acute kidney injury
WO2010143423A1 (ja) 糖尿病性腎症の検査方法
CN108700600A (zh) 用于检测和诊断肾病和牙周病的方法和组合物
EP2674755B1 (en) Method for diagnosing acute lung injury
JP7271442B2 (ja) 腎機能を診断またはモニターする方法、または腎機能障害を診断することを補助する方法
JPWO2005080982A1 (ja) Ａ型及びｂ型急性大動脈解離と急性心筋梗塞の鑑別方法及び鑑別用キット
JP5801895B2 (ja) 全身性炎症反応症候群を伴わない術後感染症の検出方法
TWI397687B (zh) 腎病變相關之生物標記的應用及其中所使用的套組
CN112805565A (zh) 对肝型脂肪酸结合蛋白质进行定量的方法、其定量用试剂盒、肾疾病的检查方法、其检查试剂盒及伴随诊断药
US8697368B2 (en) Diagnostic marker for lung cancer comprising HPαR as active ingredient
JP2007163151A (ja) 対象生物の生理状態を判定する方法
JP7307479B2 (ja) ＩｇＡ腎症診断用キット
JP5857385B2 (ja) Ａｐｅ１／ｒｅｆ−１を含有する膀胱癌診断用組成物、及びこれを利用した膀胱癌診断キット
JP7818217B2 (ja) 呼吸器感染症の重篤度判別方法および試薬
HK40049525A (en) Method and kit for quantifying liver-type fatty acid binding protein, method and kit for testing for kidney diseases, and companion diagnostic drug
JPH02293665A (ja) 腎疾患の検査方法
JP2025100373A (ja) Ａｎｃａ関連血管炎に関する血中マーカーの検出方法とその利用
WO2023277130A1 (ja) 尿細管間質障害の検出用バイオマーカー並びにその用途
JP4098020B2 (ja) 尿中のプラスミノーゲンアクチベーターインヒビター−１測定による糖尿病性腎症の進展度の判定方法
JP4907399B2 (ja) 血中腸型脂肪酸結合蛋白測定による急性腸炎の検出方法
JP2010271295A (ja) 測定試薬
CN112771377A (zh) 肝疾病的检查方法、其检查试剂盒和伴随诊断药

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210422

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20210422

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210629

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210630

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20210713

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210810

R150 Certificate of patent or registration of utility model

Ref document number: 6933834

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313115

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350